. The purpose of this communication is the detailed description of a method found to be suitable for general laboratory use, incorporating reagents readily available in Europe: the results obtained during standardization are recorded and the selected commercial preparations specified.
Substrate standardization is necessary for the assay of components of the fibrinolytic system, not only to permit reproducibility in the laboratory but, in particular, to facilitate comparison of results recorded in different centres during the development of this relatively new subject. Difficulties experienced with reproducibility are due mainly to the fact that commercially available fibrinogens and thrombins are contaminated in varying degree by other components of the fibrinolytic system, whilst human plasminogen is difficult and expensive to prepare. Procedures involving a standard clot have already been used (Christensen, 1949; Johnson and Tillett, 1952; Fletcher, 1954; Baumgarten, Ciminera, and Cole, 1960) . The purpose of this communication is the detailed description of a method found to be suitable for general laboratory use, incorporating reagents readily available in Europe: the results obtained during standardization are recorded and the selected commercial preparations specified.
The standard clot comprises fibrinogen and thrombin, to which plasminogen and activator may be added if appropriate. It is made up to a fixed volume with buffer and thus provides 'reagent' space so that the components to be tested are actually included in the fibrin clot and their intrinsic effect on the subsequent lysis time can be measured. The method depends on the fibrin clot so formed being reproducible, stable, of constant volume, and uniformly susceptible to the action of plasmin. It offers a number of advantages over others in current use. The selection of fibrin as the substrate more nearly reproduces physiological conditions than does that of casein or the synthetic esters. It is shorter and easier to use quantitatively than the fibrin plate method (Astrup and Mullertz, 1952) which has the further disadvantage that the test substance cannot actually be incorporated in the Received for publication 26 September 1963. 175 clot. Neither the special apparatus required for the 1311-labelled clot procedure nor the preparations involved in the standard thrombus (Blix, 1962) are necessary.
METHOD
Only those materials easily obtainable in Europe or prepared in the laboratory have been investigated and, when possible, more than one batch of each reagent has been tested to assess variation from batch to batch. Throughout, meticulous attention has been paid to storage and the provision of optimal conditions necessary for the maintenance of stability.
Other workers have already selected 11 ml. as a standard volume and this provides a conveniently sized test system. Basically, the clot consists of 0-2 ml. fibrinogen and 0-1 ml. thrombin, each in a pre-standardized solution, leaving a reagent space of 0-8 ml. into which plasminogen, activator, and test substances can be introduced as desired, the volume being made up by saline phosphate buffer (Appendix 1).
The test is carried out in new 75 x 12 mm. glass testtubes which have been washed in detergent, rinsed, soaked overnight in 2% HCI, and re-rinsed thoroughly with tap and then distilled water. Tubes and reagents are placed in an ice-bath. Reagents are added as rapidly as possible in the sequence saline buffer, plasminogen, fibrinogen, activator, and, finally, thrombin; several tubes can be set up together, providing that the total length of time spent in preparation is not more than one and a half minutes. A stop-watch is started as the thrombin is added, the contents of the tube are quickly mixed, preferably by means of an automatic mixer, and the tubes transferred to a water-bath at 37°C. One minute later they are examined to confirm that clotting has taken place; thereafter they are examined every 30 seconds, or at regular intervals determined by experience of the particular test being carried out. The end-point is taken as the time of complete disappearance of the clot and is recorded as the lysis time in minutes.
INTERPRETATION OF REsuLTs
The lysis times of serial dilutions of the test substances are plotted against concentration. A 'standard clot' unit of activity is the concentration required to produce complete lysis in an arbitrarily fixed time. It is convenient to select 10 minutes for this purpose.
REAGENTS
Two points in the selection of reagents merit emphasis. With all protein substrates, the varying amount of contamination must be assessed and, if possible, the cause identified (Appendix 2). The choice of buffer can be critical: either as a result of interaction with the different proteins or because of its effect upon ionic calcium, the solution used can exert an influence on results. Calcium inhibits some phases of the fibrinolytic mechanism (Bruce, 1964) and so a saline phosphate buffer (pH 7 5) has been used in the tests described in this paper because ionic calcium is removed as calcium phosphate. The inclusion of a trace of merthiolate in the buffer has not been found to influence the results of the test, and is useful in preventing the growth of contaminating moulds and algae. In the preparation of streptokinase dilutions, gelatin is added to the buffer solution because the provision of a gel serves to stabilize the streptokinase during the time taken to complete the procedures (Appendix 3). Table I ). The trace of plasminogen activator detectable on the fibrin plate was not enough to cause lysis of a standard clot in 24 hours and was, therefore, not considered relevant. The unpredictable effect of the plasminogen could be eliminated by the deliberate addition of excess plasminogen from human serum euglobulin (see later). Even though the effect of plasminogen contamination was nullified in this way, variation of the clot lysis time still occurred when 1 % solutions (w/v) of different batches of fraction I were used in the preparation of streptokinase-activated standard clots. Moreover, this could not be corrected by separating out contaminant antiplasmins by euglobulin precipitation. Calibration curves for streptokinase made with fraction I from the various batches were, however, always found to be parallel when the plasminogen level was controlled (Fig. 1) (w/v) of fraction I in the standard clot and thus controlling the ultimate amount of fibrin formed, it was found that unknown batches of fraction I could be standardized against a pre-selected control batch. Standardization Initially a streptokinase dilution curve was plotted for each of the three fibrinogen batches examined, using a standard clot mixture incorporating 1 % fibrinogen solution (Fig. 1) . The batch providing the fastest lysis time (Armour EF 0573) was selected and, thereafter, 0-2 ml. of a 1% solution of this batch (50 mg. in 5 ml. saline phosphate buffer) was used in the preparation of every standard clot.
FIBRINOGEN
Although batch EF 0573 fibrinogen was established as the reference for all subsequent estimations, the concentration of other batches of fraction I was determined which would provide similar results. Standard clots incorporating serial dilutions of the unknown fraction I were prepared in parallel with the reference fibrinogen. For this particular experiment, streptokinase in a concentration of 10 units/ml., providing a 10-minute lysis time, was diluted to 1 unit/ml., thus prolonging the time of complete lysis to 20 to 23 minutes (Table II) . The amount of fraction I in the same speed as that containing re then calculated: using a solution c in 0-2 ml., the calibration curve found to coincide exactly with reference batch within the range 50 to 0 5 units streptokinase per millilitre.
The standardization of Armour batches FA 1770 and DB 1770 (Tables II and III) showed that these could be used in the preparation of a standard clot as follows:-FA 1770: 0-2 ml. of a solution containing 37-5 mg. in 5 ml. SP buffer (0-75 % w/v).
DB 1770: 0-2 ml. of a solution containing 25 mg. in 5 ml. SP buffer (0-5 % w/v).
Other sources Warner bovine fibrinogen has been found to be free from significant contamination with activator although the batch tested contained some plasminogen (Table I) . Batches of Kabi human fibrinogen, which should be standardized as described for use in the standard clot, have also been found to be free from activator and, if necessary, the plasminogen can be removed by the method of Mosesson (1962) . Howell (1963) refers to the use of time-expired bank blood as a convenient laboratory source of human fibrinogen which can be used when plasminogen contamination does not matter: a plasma-euglobulin preparation gives a fibrinogen-plasminogen mixture free from anti-plasmin activity. THROMBIN Two commercial thrombin preparations, both of bovine origin, were assessed: Thrombin Topical (Parke, Davis) and Thrombin Reagent (Leo Laboratories). A thrombin/fibrinogen curve, prepared for each batch, showed the thrombins to be equal in their power to clot fibrinogen. The results of tests for contamination with components of the fibrinolytic system are given in Table I .
These show that each of the two batches of Thrombin Topical tested contained contaminants likely to influence (ARMOUR BOVINE PLASMA the results of tests of fibrinolytic activity; this has also I) been found by other workers (McNicol, 1962; Innes, 1962) . Only one batch of Thrombin Reagent was available: this was found to be remarkably free from con- -35°C. in measured aliquots of a solution containing 500 N.I.H. units/ml. saline in plastic containers. For use clot which lysed at the it is diluted 1 : 10 with saline phosphate buffer; this ference fibrinogen was solution will remain active for eight hours in an ice-bath. containing this quantity
It is important to use enough thrombin to convert all for streptokinase was the fibrinogen present in the system rapidly to fibrin. If the curve from the conversion is incomplete or if there is time for significant fibrinogenolysis to occur, the final amount of fibrin substrate in the test will be reduced. By using uncontaminated thrombin it is permissible to add an excess to the standard clot system, thus ensuring complete and rapid fibrin formation. Thrombin Reagent is best used in a concentration of 50 N.I.H. units/ml. and 0-1 ml. of this solution will bring about clotting in a 1-1 ml. standard clot in less than 30 seconds. PLASMINOGEN Although it is stable in blood, pure plasminogen is difficult and expensive to prepare and is unstable. It is present in Cohn plasma fraction III but, unfortunately, human fraction III is not readily available in Great Britain. Of the commercial preparations tested, Kabi human plasminogen was found to be partially activated to plasmin. The purity of the Merck Sharp & Dohme preparation would make it ideal for use in the standard clot but it is very unstable in solution and must be kept on ice: it is best used as 0-1 ml. of a solution containing 1 mg. plasminogen/ml. saline phosphate buffer. Using a concentrated solution the marked instability can be ignored for the period of the experiment.
Human serum euglobulin, prepared from pooled plasma taken from time-expired banked acid-citratedextrose blood, is a satisfactory source of plasminogen available in all clinical laboratories (Appendix 4). Serum, rather than plasma, is used to preclude inaccuracy due to the presence of further fibrinogen altering the final concentration of substrate: antiplasmins remain in the supernatant during euglobulin precipitation and can be rejected, and although anti-activators formed during the collection of blood (Flute, 1960) are precipitated with the euglobulin, their effect can be diluted out. Some activator activity persists (Table I) Typical lysis results are given in Table IV : the dilution producing the shortest lysis time is selected for use. A solution calculated to contain the required amount of plasminogen in 0-1 ml. is prepared by dilution of the stored stock solution. Unlike purified plasminogen, this solution will remain stable foi eight hours in an ice-bath, and shows no tendency towards autoactivation.
PLASMINOGEN ACTIVATORS The activators of plasminogen most generally used in laboratory estimations are streptokinase and urokinase. At present streptokinase is the cheaper and more readily available.
Streptokinase Several commercial preparations are available, each of which is suitable for use in the standard clot, provided that standardization is carried out. In the present study Varidase (Lederle) has been used: this is most satisfactory as long as precautions are taken to prevent deterioration of prepared solutions.
Varidase is supplied as freeze-dried material in vials containing 100,000 manufacturer's units. For the preparation of a stock solution 10 ml. of ice-cold normal saline is added to the vial giving a solution containing 10,000 units per ml. After mixing, the streptokinase solution is distributed in measured aliquots into plastic tubes which are immediately frozen at -35°C. One tube is retained for standardization which is carried out as soon as possible. Each vial must be standardized, but the stock solution frozen at -35°C. has been found to retain its full activity for at least one month.
Standardization All dilutions are made in gel buffer, pH 7 5, and all solutions kept in an ice-bath. Dilutions are prepared as follows:- 
APPLICATIONS OF STANDARD CLOT METHOD
The purpose of the standard clot method is not to supplant biochemical standardization, which is necessarily a highly technical commitment, but to augment the facilities of the average clinical laboratory. Its principal virtue is the ease with which the basic method can be adapted to measure the activity of plasmin, antiplasmin, activator, or anti-activator (the latter including the antagonistic effect of antistreptococcal antibodies). It is also possible to measure plasminogen concentration but as this involves the use of a different fibrinogen preparation it will be reported elsewhere.
ACTIVATOR ACTIVITY ASSAY The method is not suitable for the measurement of intrinsic plasma activator because for this it is necessary to remove all naturally occurring inhibitors from the test plasma. It is, however, very useful for estimating the activity of artificial activators; this is carried out as described for the standardization of streptokinase. The method can also be used for assessing the activity of tissue activator which does not normally occur in association with inhibitors. By the construction of a graph, as described, the amount of activator which will cause the lysis of a 11 ml. standard clot containing excess plasminogen can be determined; this is defined as one standard clot unit of activator.
ANTI-ACTIVATOR ASSAY Inhibition of plasminogen activation may be brought about by two different mechanisms. Blood itself is able to exert an inhibitory effect on activators, which is probably equally potent against the intrinsic (plasma) activator and such artificial activators as streptokinase and urokinase. This inhibition by blood is not intrinsically present in the circulation, but is developed rapidly in shed blood, the rate of development probably being dependent upon surface contact, temperature, and the presence of platelets and calcium (Flute, 1960 (Flute, , 1962 . The other form of inhibition against plasminogen activation to be found in whole blood is due to the presence of antibodies developed as a result of stimulation by heterologous protein antigens: the most important of these in humans is the anti-streptokinase antibody resulting from incidental streptococcal infections. The urokinase used so far has always been of human origin and anti-urokinase antibodies have not been reported in man, although human urokinase is probably antigenic to other species (Celander and Guest, 1960) . The inhibitory effect of antibodies is not influenced by those factors governing the production of the blood anti-activator but is present in the circulating blood: by varying the conditions of collection of the blood sample it is therefore possible to assay the inhibitory effect of antibody alone or the total inhibition due to antibody plus blood inhibitor. Measurement of antibody activity is carried out on citrated, platelet-poor plasma collected and prepared with a meticulously observed cold technique, using plastic apparatus in order to prevent activation of the blood inhibitor. For the assay of total inhibition the test sample is collected and prepared under conditions which give maximum opportunity for activation of the inhibitor.
An important application of this method is to assess the inhibition which must be overcome before thrombolytic treatment with infusion of activator can become effective. Such inhibition is due to antibody against the activator being used; the demonstrable inhibitor in shed blood can be ignored because it is not active in the circulation.
If urokinase is the activator of choice antibodies will not be present but when streptokinase is used, interference by antibodies is inevitable. Any assay must be carried out on cold-treated, non-activated, platelet-poor citrated or E.D.T.A. plasma, in order to calculate the initial dose of streptokinase which will neutralize the antibodies already present.
MEASUREMENT OF ANTI-STREPTOKINASE ANTIBODY CONCEN-
TRATION Venous blood is collected with a plastic syringe which has been cooled to 40C. (the needle is not cooled). It is placed in a pre-cooled plastic tube containing 1/10 volume of 3-8% trisodium citrate or 1/100 volume of 10% E.D.T.A. and immediately centrifuged at 3,000 r.p.m. (3,700 g) for 10 minutes at 40C. The platelet-poor plasma is transferred to a second polystyrene tube in an ice-bath by means of a polystyrene Pasteur pipette, and the test set up immediately.
While the blood is being centrifuged, streptokinase of the type to be used for the treatment is standardized as described previously and a solution containing 10 standard clot units per millilitre prepared. The test plasma is diluted 1 in 5 with saline phosphate buffer and further dilutions are made from this as shown in Table V , all tubes being kept in an ice-bath. To tubes 1-7 add 0-1 ml. streptokinase, 10 standard clot units per ml.
To tubes 8 and 9 add 005 ml. streptokinase, 10 standard clot units per ml.
All (Johnson and McCarty, 1959) .
PLASMIN ACTIViTY ASSAY The standard clot method is not used for estimating plasma plasmin activity because, as for the estimation of endogenous activator, inhibitors must be removed to unmask the fibrinolytic effect. It could be used to estimate fibrinolytic activity in pathological fibrinolytic states where the inhibitor activity has been overcome, but other tests suitable for this are available. The principal value of the standard clot method in this respect is in the assay and standardization of proprietaly brands of plasmin: it should be noted that most of these are prepared by the addition of activatorusually streptokinase-to plasminogen and therefore inevitably contain some free activator (Baumgarten et al., 1960) . Unless a plasminogen-free assay system is used, the rate of lysis of the standard clot will be a measure of the fibrinolytic potential rather than a direct function of the plasmin added.
One standard clot unit of plasmin may be defined as the amount which will lyse a standard clot in 10 minutes. Dilutions of the test material are made in saline-phosphate buffer to contain 500, 100, 50, 40, 30, 20, 10, 1, and 
0-1J
'Plasminogen is replaced by saline phosphate buffer if a plasminogenfree system is being used for the assay of plasrnin alone.
The lysis time given by each plasmin dilution is noted. Lysis times are plotted against dilution of test material on double logarithmic graph paper. From the graph the dilution which will lyse a standard clot in 10 minutes is determined; this will contain one standard clot unit of fibrinolytic activity. (Lassen, 1952) . 2 PLASMINOGEN Heated fibrin plates. Test material mixed with an equal volume of sireptokinase (1,000, 100, and 10 units/ml.) and human serum (1/100) or human activation product as a source of proactivator (Mullertz and Lassen, 1953; Hawkey, 1963) .
3 PLASMINOGEN ACTIVATOR Unheated fibrin plates and plates prepared from a euglobulin precipitate of bovine plasma fraction I. The euglobulin precipitate contains fibrinogen and plasminogen and plates prepared from it are more sensitive to minor degrees of plasmin activity than are standard unheated fibrin plates because the anti-plasmin level is reduced (Kowalski et al., 1959 
